Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

The high recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the widespread use of intravesical therapy as a supplement to TUR. Superficial bladder ...

Phase 3 Trial Design The randomized, open-label, single-center trial enrolled 63 patients with primary or recurrent NMIBC who had not received prior adjuvant intravesical therapy. Additional inclusion ...

and squamous cell carcinoma—none of which are considered responsive to intravesical therapy. Understanding the status of the normal-appearing mucosa is important in identifying patients with ...

including Ferring's intravesical gene therapy Adstiladrin (nadofaragene firadenovec) and ImmunityBio's IL-15 receptor agonist Anktiva (nogapendekin alfa inbakicep), which both launched in the US ...

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ.

The standard of care includes complete transurethral resection of bladder tumor, often followed by intravesical therapy such as Bacillus Calmette-Guérin (BCG). However, BCG has a treatment failure ...

NDV-01 is a novel, investigational, sustained-release gemcitabine/docetaxel formulation, designed as a ready-for-use intravesical therapy for the treatment of NMIBC. The U.S. prevalence of NMIBC ...